FIERCELY FOCUSED
ON SCIENCE

OUR PIPELINE

MS

ONCOLOGY
REGIMEN DIsease Preclinical Phase 1 Phase 2 Phase 3 Registration Status Learn More

Single Agent

Ublituximab monotherapy anti-CD20 mAb Relapsing MS
ULTIMATE I and II
learnmore
Umbralisib monotherapy P13k-delta & CK1 -epsilon inhibitor R/R MZL
UNITY-NHL
PDUFA: 2/15/2021 learnmore
Umbralisib monotherapy R/R FL
UNITY-NHL
PDUFA: 6/15/2021 learnmore

Combination

Umbralisib + ublituximab (U2) R/R NHL
UNITY-NHL
learnmore
Umbralisib + ublituximab (U2) Frontline and R/R CLL
UNITY-CLL
learnmore
Ublituximab + ibrutinib R/R high-risk CLL
GENUINE
learnmore
Umbralisib + ublituximab + venetoclax Frontline and R/R CLL
ULTRA-V
learnmore
Umbralisib + ublituximab + TG-1701 (BTKi) Frontline and R/R CLL & NHL
learnmore

Early Pipeline

Cosibelimab (TG-1501): anti-PD-L1 mAb B-cell malignancies
learnmore
TG-1701: BTK inhibitor B-cell malignancies
learnmore
TG-1801: anti-CD47/CD19 bispecific mAb B-cell malignancies
learnmore
TG-1601: BET inhibitor B-cell malignancies
learnmore
ENROLLMENT COMPLETED
ENROLLMENT ONGOING

The safety and efficacy of our investigational compounds have not been established. These products have not been approved by the US Food and Drug Administration or other regulatory authorities.